Your browser doesn't support javascript.
loading
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Guerin, Mathilde; Rezai, Keyvan; Isambert, Nicolas; Campone, Mario; Autret, Aurélie; Pakradouni, Jihane; Provansal, Magali; Camerlo, Jacques; Sabatier, Renaud; Bertucci, François; Charafe-Jauffret, Emmanuelle; Hervieu, Alice; Extra, Jean-Marc; Viens, Patrice; Lokiec, François; Boher, Jean-Marie; Gonçalves, Anthony.
Affiliation
  • Guerin M; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
  • Rezai K; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France.
  • Isambert N; Centre Georges-Francois Leclerc, Dijon, France.
  • Campone M; Institut de Cancérologie de L'Ouest, Nantes, France.
  • Autret A; Institut Paoli-Calmettes, Department of Clinical Research and Innovations, Marseille, France.
  • Pakradouni J; Institut Paoli-Calmettes, Department of Clinical Research and Innovations, Marseille, France.
  • Provansal M; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
  • Camerlo J; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
  • Sabatier R; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
  • Bertucci F; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
  • Charafe-Jauffret E; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Biopathology, CRCM, Marseille, France.
  • Hervieu A; Centre Georges-Francois Leclerc, Dijon, France.
  • Extra JM; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
  • Viens P; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
  • Lokiec F; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France.
  • Boher JM; Institut Paoli-Calmettes, Department of Clinical Research and Innovations, Marseille, France; Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Santé & Traitement de L'Information Médicale, Marseille, France.
  • Gonçalves A; Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France. Electronic address: goncalvesa@ipc.unicancer.fr.
Eur J Cancer ; 86: 28-36, 2017 11.
Article in En | MEDLINE | ID: mdl-28950146
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Morpholines / Receptor, ErbB-2 / Protein Kinase Inhibitors / Trastuzumab / Antineoplastic Agents, Immunological / Aminopyridines Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Eur J Cancer Year: 2017 Document type: Article Affiliation country: France Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Morpholines / Receptor, ErbB-2 / Protein Kinase Inhibitors / Trastuzumab / Antineoplastic Agents, Immunological / Aminopyridines Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Eur J Cancer Year: 2017 Document type: Article Affiliation country: France Country of publication: United kingdom